The Pfizer and BioNTech vaccine against Covid-19 demonstrated “100% efficacy” among adolescents aged between 12 and 15 years old, the company announced.

“We share the urgency to expand the authorisation of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” said Albert Bourla, chair and chief executive officer of Pfizer, said on 31 March.